Effect of Pelvic Rehabilitation After Low Anterior Resection for Cancer Rectum. - A Randomised Controlled Trial

This study will investigate the effects of pelvic floor rehabilitation (PFR) on bowel function and quality of life in patients who have undergone low anterior resection (LAR) for rectal cancer. The study aims to provide a more comprehensive understanding of effective aftercare for these patients. Here are the key components of the study protocol:

Study Design

Type: Randomized controlled trial.

Participants: Patients who have undergone LAR for rectal cancer.

Interventions: Pelvic floor rehabilitation compared to usual care.

Primary Outcomes: Fecal incontinence.

Secondary Outcomes: Quality of life, LARS score.

Procedures. Screening and Enrollment: Pateint with rectal cancer undergoing sphincter preserving surgeries and who are willing to participate will be enrolled after thorugh explaination of the study.

Randomization: Post three months following Low anterior resection or post 6 weeks following closure of diversion ileostomy, participants will be randomly assigned to either the PFR group or the usual care group using computer generated randomization.

Intervention: The PFR group will receive a structured pelvic floor rehabilitation program by a trained pelvic physiotherapist along with usual care. The PFR program includes three components:

1. Pelvic Floor Muscle Training: Focused on increasing maximum strength, extending contraction duration, and enhancing pelvic floor muscle coordination.
2. Biofeedback: A behavior-based therapy with a feedback loop, enabling patients to visualize the impact of muscle actions and improve pelvic floor movements.
3. Rectal Balloon Training: Simulating resistance to the urge to defecate, aiding in LARS prevention. This will be carried out as in-person sessions weekly for the first month and biweekly for the next 2 months, totaling 8 sessions over 3 months. Additionally, home sessions will be conducted under phone guidance. Patients are required to fill out relevant questionnaires before and after completing the PFR program. The usual care group will receive standard post-surgical care. Baseline scores: Wexner's score, LARS score, EORTC CR 29 score taken before the start of the study. Follow-up: Participants will be followed for three months and Wexner's scores, LARS, EORTC CR 29 score will be taken. Quality Assurance Data Validation: Data entered into the registry will be validated against predefined rules for range and consistency. Source Data Verification: Data accuracy will be assessed by comparing registry data to external sources such as medical records. Data Dictionary: Detailed descriptions of each variable, including source, coding information, and normal ranges, will be maintained. Standard Operating Procedures (SOPs) Recruitment and Data Collection: SOPs will ensure consistent recruitment and data collection processes. Data Management and Analysis: Procedures for managing and analyzing data will be clearly defined. Adverse Event Reporting: SOPs will include protocols for reporting adverse events. Change Management: Procedures for handling changes in the study protocol will be in place. Sample Size Assessment: Previous Studies: Previous research has shown a reduction of Wexner's incontinence scores by 5 points (SD=8) with pelvic floor rehabilitation (PFR) treatment (6-9). Study Design: The study was designed with a significance level (alpha error or Type I error) set at 0.05 and a power of the test (beta error or Type II error) at 0.20. A total of 64 patients were initially calculated to be necessary to detect a statistically significant difference between treatment groups. Sample Size Calculation: Considering an anticipated drop-out rate of 20%, the total sample size required for the study was adjusted to 77 patients. Plan for Missing Data Procedures will be in place to address missing data, including how to handle variables reported as missing or inconsistent. We shall evaluate the extent of missing data for each variable and use appropriate methods for handling missing data such as imputation techniques or sensitivity analyses. Statistical Analysis Plan: Study Design The study involves a randomized controlled trial (RCT) where patients undergoing Sphincter sparing-rectal cancer surgery are randomized into two groups: Standard Group: Receives standard post-operative care. PFR Group: Receives pelvic floor physiotherapy in addition to standard care. Outcome Measures The following continuous variables will be measured before starting the intervention and after 3 months: Wexner's Scores: Assessing fecal incontinence severity. LARS Scores (Low Anterior Resection Syndrome): Assessing bowel dysfunction. EORTC CR 29 Scores (European Organisation for Research and Treatment of Cancer Colorectal Cancer Module): Assessing quality of life related to colorectal cancer. Statistical Hypotheses Within-Group Comparison: Null Hypothesis (H0): There is no significant difference in mean scores (Wexner's, LARS, EORTC CR 29) before and after intervention within each group (Standard and PFR). Between-Group Comparison: Null Hypothesis (H0): There is no significant difference in the change in mean scores (Wexner's, LARS, EORTC CR 29) from before to after intervention between the Standard and PFR groups. Statistical Methods Descriptive Statistics: Mean and standard deviation (SD) for continuous variables (Wexner's, LARS, EORTC CR 29 scores) at baseline and after 3 months in each group. Within-Group Analysis: Paired t-tests or Wilcoxon signed-rank tests (depending on normality) to compare mean scores before and after intervention within each group (Standard and PFR). Between-Group Analysis: Independent samples t-tests or Mann-Whitney U tests (depending on normality) to compare the change in mean scores (after - before) between the Standard and PFR groups. Adjustments: Adjustments for potential confounding factors such as age, gender, and baseline scores using analysis of covariance (ANCOVA) if necessary. Effect Size: Calculate effect sizes (e.g., Cohen's d for t-tests, r for Mann-Whitney U tests) to quantify the magnitude of differences observed. Statistical Significance: We shall set the significance level (alpha) at 0.05 to determine statistical significance. Software Utilize statistical software (SPSS) for data analysis. Reporting We shall present results with confidence intervals and p-values, providing clear interpretations of findings in relation to clinical significance and study objectives. This detailed description outlines the comprehensive approach taken to ensure the study's rigor and reliability, aiming to fill significant gaps in current knowledge about effective aftercare for rectal cancer patients.